Summary
DexCom Inc. (DXCM) reported strong revenue growth in the third quarter of 2014, with product revenues increasing by 59.7% year-over-year to $67.9 million. This growth was primarily driven by increased sales volume of their G4 PLATINUM continuous glucose monitoring system, indicating growing market acceptance. The company also saw an improvement in gross profit margin due to a higher sales mix of the more profitable G4 PLATINUM system. Despite continued investment in research and development and selling, general, and administrative expenses to support growth, the company is demonstrating positive momentum in revenue generation and market penetration. Financially, DexCom generated positive net cash from operating activities for the nine months ended September 30, 2014, a significant improvement from the prior year. The company ended the quarter with a healthy cash balance of $74.9 million, providing a cushion for ongoing operations and development. Management believes current resources are sufficient to meet anticipated cash requirements through at least September 30, 2015. The report highlights the expanding commercialization of the G4 PLATINUM system, including pediatric and professional use indications, and the recent FDA approval of the DexCom SHARE remote monitoring system, which are key drivers for future growth.
Financial Highlights
45 data points| Revenue | $67.90M |
| Cost of Revenue | $21.80M |
| Gross Profit | $47.20M |
| R&D Expenses | $18.50M |
| SG&A Expenses | $33.70M |
| Operating Expenses | $52.20M |
| Operating Income | -$5.00M |
| Interest Expense | $200K |
| Net Income | -$5.20M |
| Shares Outstanding (Basic) | 303.20M |
| Shares Outstanding (Diluted) | 304.40M |
Key Highlights
- 1Product revenues surged by 59.7% to $67.9 million in Q3 2014 compared to Q3 2013, driven by strong sales volume of the G4 PLATINUM system.
- 2Gross profit increased by 66.4% to $46.1 million in Q3 2014, with gross profit margin improving due to a favorable product mix (G4 PLATINUM vs. SEVEN PLUS).
- 3Significant year-over-year increases in Research & Development ($18.5M vs. $11.8M) and Selling, General & Administrative ($33.7M vs. $21.6M) expenses reflect ongoing investment in future growth and commercialization.
- 4Net cash provided by operating activities was $15.2 million for the nine months ended September 30, 2014, a substantial improvement from $2.0 million net cash used in the same period of 2013.
- 5The company received FDA approval for the DexCom SHARE remote monitoring system on October 17, 2014, enabling remote monitoring of glucose data for users.
- 6The G4 PLATINUM system received expanded indications for pediatric use (February 2014) and professional use (June 2014), broadening its market reach.
- 7As of September 30, 2014, DexCom had $74.9 million in cash, cash equivalents, and short-term marketable securities, with management confident in meeting liquidity needs through at least September 2015.